Home /Biblio

Biblio

Found 399 results
Author Keyword Title Type [ Year(Asc)]
2011
J. A. Ledermann, Marth, C., Carey, M. S., Birrer, M. J., Bowtell, D. D. L., Kaye, S. B., McNeish, I., Oza, A. M., Scambia, G., Rustin, G. J. S., Stehman, F. B., Gershenson, D., Thomas, G., Berns, E. M. J. J., Casado, A., Ottevanger, N., Hilpert, F., Kim, B. - G., Okamoto, A., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 763-70, 2011.
R. P. Symonds, Davidson, S. E., Chan, S., Reed, N. Simon, McMahon, T., Rai, D., Harden, S., Paul, J., Group, S. Gynaecolog, and Centre, B. West of Sc, “SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer”, Gynecol Oncol, vol. 123, pp. 105-9, 2011.
E. Greimel, Bjelic-Radisic, V., Pfisterer, J., Hilpert, F., Daghofer, F., Pujade-Lauraine, E., du Bois, A., Group, A. Gynaekolog, and de l'Ovaire, Gd'Investig, “Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials”, Support Care Cancer, vol. 19, pp. 1421-7, 2011.
2010
G. Mangili, Scarfone, G., Gadducci, A., Sigismondi, C., Ferrandina, G., Scibilia, G., Vigano, R., Tateo, S., Villa, A., and Lorusso, D., “Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)”, Gynecol Oncol, vol. 119, pp. 48-52, 2010.
E. L. Trimble, Birrer, M. J., Hoskins, W. J., Marth, C., Petryshyn, R., Quinn, M., Thomas, G. M., Kitchener, H. C., Aghajanian, C., Alberts, D. S., Armstrong, D., Brown, J., Coleman, R. L., Colombo, N., Eisenhauer, E., Friedlander, M. Leonard, Fujiwara, K., Hunsberger, S., Kaye, S. B., Ledermann, J. A., Lee, S., Look, K., Mannel, R., McNeish, I. A., Minasian, L. M., Oza, A. M., Paul, J., Poveda, A. M., Pujade-Lauraine, E., Schoenfeldt, M., Swart, A. Marie, von Gruenigen, V., and Wenzel, L. B., “Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.”, Int J Gynecol Cancer, vol. 20, no. 7, pp. 1290-8, 2010.
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con, “The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report”, Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
T. J. Perren, Swart, A. Marie, Pfisterer, J., Ledermann, J. A., Lortholary, A., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., “. ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopia”, Ann Oncol , vol. 21, no. Suppl 8, abstr LBA4, 2010.
M. C. Gainford, Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., and Friedlander, M. Leonard, “Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study”, Int J Gynecol Cancer, vol. 20, pp. 75-81, 2010.
C. M Gainford, Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., and Friedlander, M. Leonard, “Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study.”, Int J Gynecol Cancer, vol. 20, no. 1, pp. 75-81, 2010.
I. Ray-Coquard, Weber, B., Lotz, J. P., Tournigand, C., Provencal, J., Mayeur, D., Treilleux, I., Paraiso, D., Duvillard, P., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., “Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients”, Gynecol Oncol, vol. 119, pp. 53-9, 2010.
J. Alexandre, Ray-Coquard, I., Selle, F., Floquet, A., Cottu, P., Weber, B., Falandry, C., Lebrun, D., Pujade-Lauraine, E., and , “Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience”, Ann Oncol, vol. 21, pp. 2377-81, 2010.
I. B. Vergote, Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. Benedetti, Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G. C. E., Pecorelli, S., and Reed, N. Simon, “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.”, N Engl J Med, vol. 363, no. 10, pp. 943-53, 2010.
E. Pujade-Lauraine, Wagner, U., Åvall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I. B., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G. B., Jackisch, C., Joly, F., Brown, C., Le Fur, N., and du Bois, A., “Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.”, J Clin Oncol, vol. 28, no. 20, pp. 3323-9, 2010.
S. Pecorelli, Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsaros, D., Lhommé, C., Lissoni, A., Vermorken, J. B., du Bois, A., Poveda, A. M., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., and Guastalla, J. P., “Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.”, Ann Oncol, vol. 21, no. 4, pp. 759-65, 2010.
M. P. Smerdel, Steffensen, K. D., Waldstrom, M., Brandslund, I., and Jakobsen, A., “The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab”, Gynecol Oncol, vol. 118, pp. 167-71, 2010.
H. Mackay, Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. Marie, Siddiqui, N. Ahmad, Colombo, N., Bookman, M. A., Pfisterer, J., du Bois, A., and InterGroup, G. Cancer, “Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer”, Int J Gynecol Cancer, vol. 20, pp. 945-52, 2010.
M. Quinn, “Progress in ovarian cancer trials: the GCIG consensus model–is bigger, better?”, Gynecol Oncol, vol. 119, pp. 5-6, 2010.
S. Takakura, Takano, M., Takahashi, F., Saito, T., Aoki, D., Inaba, N., Noda, K., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, “Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study”, Int J Gynecol Cancer, vol. 20, pp. 240-7, 2010.
T. Högberg, Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A., Sorbe, B., Andersson, H., Grenman, S., Lundgren, C., Rosenberg, P., Boman, K., Tholander, B., Scambia, G., Reed, N. Simon, Cormio, G., Tognon, G., Clarke, J., Sawicki, T., Zola, P., and Kristensen, G. B., “Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies”, Eur J Cancer, vol. 46, pp. 2422-31, 2010.
A. Fagotti, Fanfani, F., Vizzielli, G., Gallotta, V., Ercoli, A., Paglia, A., Costantini, B., Vigliotta, M., Scambia, G., and Ferrandina, G., “Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?”, Gynecol Oncol, vol. 116, pp. 72-7, 2010.
S. A. Welch, Hirte, H., Elit, L., Schilder, R. J., Wang, L., Macalpine, K., Wright, J. J., and Oza, A. M., “Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium”, Int J Gynecol Cancer, vol. 20, pp. 787-93, 2010.
B. Trimbos, Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M. E. L., and Casado, A., “Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.”, J Natl Cancer Inst, vol. 102, no. 13, pp. 982-7, 2010.
2009
P. Blake, Swart, A. Marie, Orton, J., Kitchener, H. C., Whelan, T., Lukka, H., Eisenhauer, E., Bacon, M., Tu, D., Parmar, M. K. B., Amos, C., Murray, C., and Qian, W., “Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.”, Lancet, vol. 373, no. 9658, pp. 137-46, 2009.
S. Pignata, Scambia, G., Savarese, A., Breda, E., Sorio, R., Pisano, C., Lorusso, D., Cognetti, F., A. Lombardi, V., Gebbia, V., Scollo, P., Morabito, A., Signoriello, G., and Perrone, F., “Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial”, Oncology, vol. 76, pp. 49-54, 2009.
N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial”, Lancet, vol. 374, pp. 1331-8, 2009.

Pages